Ranbaxy Laboratories is disappointed with the Decision by the European Commission to rule its patent settlement agreement with Lundbeck, covering the molecule Citalopram, anti-competitive, and intends to appeal the Decision to the General Court of the European Union (EU). These events took place over ten years ago, and the company considers that the Commission has misunderstood the facts and misapplied the law. The company believes it has strong grounds of appeal. Ranbaxy respects, and is committed to conducting its business in compliance with, European law, and is dedicated to offering high quality, affordable medicines for the benefit of patients, prescribers, customers and the European healthcare system.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
